Product nameAnti-Met (c-Met) antibody [EPR22436-24]
See all Met (c-Met) primary antibodies
DescriptionRabbit monoclonal [EPR22436-24] to Met (c-Met)
Tested applicationsSuitable for: WB, ICC/IF, Flow Cyt, IPmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Mouse
Recombinant fragment within Human Met (c-Met) aa 1-550. The exact sequence is proprietary.
Database link: P16056
- WB: B16-F10 and NIH/3T3 whole cell lysate. ICC/IF: B16-F10 cells. Flow: NIH/3T3 cells. IP: B16-F10 whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab216330 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Predicted molecular weight: 155 kDa.|
FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
Note=Defects in MET may be associated with gastric cancer.
Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
Contains 3 IPT/TIG domains.
Contains 1 protein kinase domain.
Contains 1 Sema domain.
DomainThe kinase domain is involved in SPSB1 binding.
modificationsDephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
- Information by UniProt
- AUTS9 antibody
- c met antibody
- D249 antibody
All lanes : Anti-Met (c-Met) antibody [EPR22436-24] (ab216330) at 1/1000 dilution
Lane 1 : B16-F10 (mouse melanoma mixture of spindle-shaped and epithelial-like cells) whole cell lysate
Lane 2 : NIH/3T3 (mouse embryonic fibroblast) whole cell lysate
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 155 kDa
Observed band size: 175 kDa why is the actual band size different from the predicted?
Blocking/diluting buffer and concentration: 5% NFDM/TBST
Exposure time: 26 seconds.
Negative control: NIH/3T3 (PMID: 21496277; PMID: 8197126; PMID 9888438)
The molecular weight observed is consistent with what has been described in the literature (PMID: 8710887).
Met (c-Met) was immunoprecipitated from 0.35mg of B16-F10 (Mouse melanoma mixture of spindle-shaped and epithelial-like cells) whole cell lysate using ab216330 at 1/30 dilution. WB was performed on the immunoprecipitate using ab216330 at 1/1000 dilution, followed by the VeriBlot for IP Detection Reagent (HRP) (ab131366) at 1/1000 dilution.
Lane 1: B16-F10 whole cell lysate 10µg (input).
Lane 2: ab216330 IP in B16-F10 whole cell lysate.
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab216330 in B16-F10 whole cell lysate.
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 30 seconds.
Flow cytometric analysis of 4% paraformaldehyde-fixed NIH/3T3 (Mouse embryonic fibroblast, Left) / B16-F10 (Mouse melanoma mixture of spindle-shaped and epithelial-like cells, Right) labeling Met (c-Met) with ab216330 at 1/500 dilution (red) compared with a Rabbit monoclonal IgG (ab172730, Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody, Blue). A Goat anti rabbit IgG (Alexa Fluor® 488, ab150077) was used as the secondary antibody at 1/2000 dilution.
Negative control: NIH/3T3(PMID: 21496277, 8197126, 9888438).
Gated on viable cells.
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized B16-F10 (mouse melanoma mixture of spindle-shaped and epithelial-like cells) and NIH/3T3 (mouse embryonic fibroblast) cells labelling Met (c-Met) with ab216330 with ab216330 at 1/50 dilution, followed by a AlexaFluor®488 Goat anti-Rabbit secondary (ab150077) at 1/1000 dilution (green). Confocal image showing membranous and cytoplasmic staining in B16-F10 cell line. Tubulin was counterstained using an Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) at 1/200 dilution. The nuclear counterstain was DAPI (Blue).
Negative control: NIH/3T3 (PMID: 21496277, 8197126, 9888438)
ab216330 has not yet been referenced specifically in any publications.